Floatz logo

Lvivo-Tavec400 Product

Progressive Multiple Sclerosis (PMS)

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

182 Active assets in the Progressive Multiple Sclerosis (PMS) cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

Lvivo-Tavec400 Product is also rated in:

plasma cell myelomaDormant
C
Indicative ·
33 / 100
View asset →
systemic lupus erythematosusDormant
NR
Indicative ·
/ 100
View asset →
immunoglobulin G4-related sclerosing diseaseDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →